Eli Lilly Ropes In Lupin For A Big Push For Its Insulin Brands In India
This article was originally published in PharmAsia News
MUMBAI - As Pfizer Inc. warms up for an entry into the rapidly growing Indian insulin market, Eli Lilly & Co., which is already established in the Indian market, is looking to strengthen its franchise via a strategic collaboration with Lupin Ltd. - an Indian company making significant strides in the anti-diabetes, cardiology, nephrology and respiratory segments
You may also be interested in...
Lilly says emerging markets represent “clear and significant opportunity” despite recent difficulties.
With an eye on diabetes and non-communicable diseases, Lilly taps new leadership in India.
Novartis will compete against market leader Cipla to make a dent in the emerging Indian COPD space.